A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 02 Apr 2025
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms QUASAR
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
- 10 Oct 2024 According to a Johnson & Johnson media release, results findings from this trial being presented in 4 Podium Presentations and 1 Moderated Poster at the United European Gastroenterology (UEG) Week 2024.
- 10 Oct 2024 Results from this trial presented in a Johnson & Johnson media release.
- 10 Oct 2024 According to a Johnson & Johnson media release, results from this Phase 3 QUASAR maintenance study presented presented at the United European Gastroenterology (UEG) Week 2024.